SCHEMBL761282

SCHEMBL761282

CSc1ncc(C(N)=O)c(Nc2ccc3cn[nH]c3c2)n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 15/20 0.66
DAPK3 O43293 2/20 0.46
PRKD3 O94806 2/20 0.46
MAP4K4 O95819 2/20 0.46
PAK4 O96013 2/20 0.46
PIM1 P11309 2/20 0.46
PRKACA P17612 2/20 0.46
CDK2 P24941 2/20 0.46
FLT3 P36888 2/20 0.46
CSNK1A1 P48729 2/20 0.46
CLK2 P49760 2/20 0.46
CDK9 P50750 2/20 0.46
JAK3 P52333 2/20 0.46
CDK5 Q00535 2/20 0.46
MAP4K2 Q12851 2/20 0.46
STK3 Q13188 2/20 0.46
DYRK1A Q13627 2/20 0.46
PKN2 Q16513 2/20 0.46
HIPK2 Q9H2X6 2/20 0.46
CLK4 Q9HAZ1 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6771473 0.91 SYK (0.66) SYKJAK3ROCK2EGFRROCK1
SCHEMBL761284 0.90 SYK (0.54) SYKDAPK3PRKD3MAP4K4PAK4
SCHEMBL6769860 0.88 SYK (0.52) SYKDAPK3PRKD3MAP4K4PAK4
SCHEMBL20354302 0.88 SYK (0.52) SYKDAPK3PRKD3MAP4K4PAK4
SCHEMBL6766065 0.87 SYK (0.51) SYKDAPK3PRKD3MAP4K4PAK4
SCHEMBL762039 0.85 SYK (0.67) SYKMAPK1HTTEGFR
SCHEMBL6610211 0.84 SYK (0.55) SYKDAPK3PRKD3MAP4K4PAK4
SCHEMBL6608523 0.84 SYK (0.48) SYKDAPK3PRKD3MAP4K4PAK4
SCHEMBL10242654 0.83 SYK (0.73) SYKDAPK3PRKD3MAP4K4PAK4
SCHEMBL10241915 0.83 SYK (0.73) SYKDAPK3PRKD3MAP4K4PAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200239458-A1 INHIBITORS OF PROTEIN KINASES ALEXION PHARMACEUTICALS, INC. 2020-07-30 US disclosed
US-20180186783-A1 INHIBITORS OF PROTEIN KINASES ALEXION PHARMACEUTICALS, INC. 2018-07-05 US disclosed
US-20180186783-A1 INHIBITORS OF PROTEIN KINASES ALEXION PHARMACEUTICALS, INC. 2018-07-05 US disclosed
US-9868729-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2018-01-16 US disclosed
US-9868729-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2018-01-16 US disclosed
US-9579320-B2 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2017-02-28 US disclosed
EP-2321283-B1 2,6-DIAMINO-PYRIMIDIN-5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS PORTOLA PHARM INC (US) 2016-07-13 EP disclosed
US-20150297595-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. 2015-10-22 US disclosed
US-20150297595-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. 2015-10-22 US disclosed
EP-2323993-B1 2,6-DIAMINO- PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS PORTOLA PHARM INC (US) 2015-06-03 EP disclosed
US-20100048567-A1 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS INC. (US) 2010-02-25 US disclosed
US-20100048567-A1 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS INC. (US) 2010-02-25 US disclosed
US-20090318407-A1 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-24 US disclosed
US-20090318407-A1 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-24 US disclosed
WO-2009145856-A1 2, 6-DIAMINO-PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-03 WO disclosed
WO-2009136995-A2 INHIBITORS OF SYK PROTEIN KINASE PORTOLA PHARMACEUTICALS, INC. (US) 2009-11-12 WO disclosed
US-6762189-B1 HEPATITIS B VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS ANTIPROLIFERATION AGENTS; REDUCED CHANCE OF TOXICITY, SIDE EFFECTS, AND DEVELOPMENT OF RESISTANT VIRAL STRAINS DONG WHA PHARM. IND. CO., LTD. (KR) 2004-07-13 US disclosed
EP-1235806-A4 NOVEL 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES DONG WHA PHARM IND CO LTD (KR) 2004-02-04 EP disclosed
EP-1235806-A1 NOVEL 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD. (KR) 2002-09-04 EP disclosed
WO-2001038308-A1 NOVEL 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES DONG WHA PHARM. IND. CO., LTD (KR) 2001-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318407-A1 Inhibitors of protein kinases SYK, BTK, JAK1 SYK 1/4885DAPK3 247/4885PRKD3 345/4885
US-20150297595-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES SYK, BTK, JAK1 SYK 1/4885DAPK3 270/4885PRKD3 422/4885
US-20200239458-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK1 SYK 1/4885DAPK3 247/4885PRKD3 345/4885
US-20180186783-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK1 SYK 1/4885DAPK3 247/4885PRKD3 345/4885
US-20100048567-A1 Inhibitors of syk and JAK protein kinases SYK, BTK, JAK1 SYK 1/4885DAPK3 270/4885PRKD3 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.